Abstract. In a mouse model of human lung cancer, intratumoral distribution between 3'-deoxy-3'-[ 
Introduction
Positron emission tomography (PET) is widely used for cancer detection, staging and monitoring the response to therapy. 18 F-FLT) are commonly used PET tracers for imaging glucose metabolism and cell proliferation, respectively (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . In a mouse model of human lung cancer, it has been previously demonstrated that intratumoral distribution between 18 F-FLT and 18 F-FDG was mutually exclusive. 18 F-FLT accumulated primarily in proliferating cancer cells, whereas 18 F-FDG accumulated in hypoxic cancer cells that are less proliferative (13) (14) (15) (16) . To the best of our knowledge, intratumoral distribution of 18 F-FLT and 18 F-FDG in patients with lung cancer has not been previously reported.
Differential diagnosis of malignant pulmonary lesions may be challenging. Computed tomography (CT) is the method of choice for the diagnosis of pulmonary lesions. PET/CT imaging reflects the biological and metabolic aspects of pulmonary lesions (17) . 18 F-FDG PET/CT has been widely used for the diagnosis of pulmonary lesions; however, false-negative as well as false-positive results are frequently observed (17, 18) . 18 F-FLT is a positron radioactive tracer that reflects cancer cell proliferation. Therefore, 18 F-FLT may be a useful tool for the diagnosis of pulmonary lesions (19) .
In the present study, it was hypothesized that the mutually exclusive distribution pattern between 18 F-FLT and 18 F-FDG described in animal tumor models may apply to patients with lung malignancies as well. To examine this hypothesis, patients with pulmonary lesions that initially underwent a 18 F-FDG PET/CT scan and subsequently a 18 F-FLT PET/CT scan were studied.
Materials and methods
Patients. The present study was approved by the Institutional Review Boards of the Inner Mongolia Medical University (Hohhot, China) and the Soochow Medical University (Jiangsu, China). Written informed consent was obtained from all patients prior to participation. The Institutional Review Board of the University of Louisville (Louisville, KY, USA) approved data transfer and use. From June 2013 to August 2015, a total of 55 patients (Table I) PET/CT imaging protocol. PET/CT images were obtained using a GE Discovery ST PET/CT scanner. Prior to 18 F-FDG PET scanning, patients were instructed to fast for >6 h and their blood glucose levels were determined to be <6 mmol/l. Whole body 18 F-FDG PET/CT scans were performed 1 h after intravenous administration of 3.7 MBq/kg 18 F-FDG. Subsequently, 3 days after 18 F-FDG imaging, local thoracic 18 F-FLT PET/CT scans were performed, 1 h after the injection of 18 F-FLT (3.7 MBq/kg). Spiral CT scans (voltage, 120 kV; current, 160-220 mA) were conducted for attenuation correction and anatomy referral.
A board of three certified physicians in nuclear medicine assessed the PET/CT images. Visual analysis to score lesion radioactivity uptake of each tracer was performed (20) . The maximal standardized uptake value (SUV max ) was used to spatially compare the intralesional distribution of 18 F-FDG and 18 F-FLT. Histological examination of the lesions was performed for all patients by board-certified pathologists at the Department of Pathology (Affiliated Hospital of Inner Mongolian Medical University). Routine hematoxylin and eosin (H&E) staining was performed. Briefly, slides containing 5 µm paraffin sections were placed on a slide holder, deparaffinized and rehydrated. Sections were treated with hematoxylin solution, dipped 8-12 times in acid ethanol to destain, and stained for 30 sec with eosin. H&E stain imaging was developed with a light microscope at x100 magnification.
Statistical analysis. SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA) was used to analyze the data using a χ 2 test. P<0.05 was considered to indicate a statistically significant difference.
Results
The clinical information and PET/CT results of the patient cohort are summarized in 
Discussion
It has previously been reported based on studies using mouse non-small cell lung cancer models that 18 F-FDG accumulates in hypoxic regions, whereas 18 F-FLT accumulates in well-oxygenated proliferating cells. Additionally, it has been demonstrated that the intratumoral distribution of 18 F-FDG and 18 F-FLT is mutually exclusive (13, 14) . In the present study, the association between 18 F-FDG and 18 F-FLT uptake was further elucidated in patients with lung cancer.
In the present study, it was demonstrated that intratumoral 18 F-FDG and 18 F-FLT accumulation is mutually exclusive. It was observed that regions with increased 18 F-FDG accumulation were mainly associated with decreased 18 F-FLT uptake. This is consistent with previous preclinical results in mouse lung cancer models (13-16). Intratumoral heterogeneity of 18 F-FLT accumulation reflected the heterogeneous distribution of hypoxic (increased 18 F-FDG uptake) and highly proliferative (increased 18 F-FLT uptake) cancer cells; in agreement with previously reported preclinical results (13) (14) (15) (16) . 18 F-FDG PET/CT is widely used in clinical practice for the detection of malignancies. However, it is not a cancer-specific tracer as it accumulates in hypoxic tissues regardless of malignant phenotype (10,13,15) . Even though benign lesions present mainly low 18 F-FDG uptake, in certain cases increased 18 F-FDG accumulation is observed in inflammatory diseases including tuberculosis. Activated macrophages and other inflammatory cells may result in enhanced 18 F-FDG accumulation in benign conditions including pneumonia, bronchiectasis, pulmonary tuberculosis, fungal infections, sarcoidosis, histoplasmosis and granuloma (21, 22) . Macrophages and other inflammatory cells, frequently observed in necrotic regions of inflammatory lesions, accumulate increased levels of 18 F-FDG possibly due to the hypoxic microenvironment (23). In the present study, 18 F-FDG and 18 F-FLT PET/CT scan uptake, performed with a 3-day interval, were compared in patients with lung lesions. A mismatch in the intralesional 18 F-FLT and 18 F-FDG accumulation was observed particularly in lung malignancies compared with benign lesions (Table I) . Therefore, on the basis of the results of the present study, it is suggested that this mismatch may serve as an indicator of lung malignancy.
In well-differentiated slow-growing tumors, including bronchiole alveolar carcinomas, false-negative 18 F-FDG PET results have been reported (20, 24) . This may be attributed to to the absence of hypoxic microenvironment of slowgrowing malignancies"
18 F-FDG is mainly considered as a hypoxia-specific rather than a tumor avid tracer (13, 15, 16) . This explains why 18 F-FDG exhibited relatively low specificity in distinguishing malignant from benign lesions. It has been demonstrated that the combination of 18 F-FLT and 18 F-FDG, either as separate PET scans performed on subsequent days or as one scan using a 18 F-FLT and 18 F-FDG cocktail, may be superior to an 18 F-FDG scan for accurate disease detection (14) . 18 F-FDG mainly accumulates in hypoxic regions, whereas 18 F-FLT accumulates in highly proliferating cells (6, 7, 13, 14) . The use of 18 F-FLT and 18 F-FDG cocktail PET may have an advantage compared with individual tracer PET. A clinical trial for 18 F-FLT and 18 F-FDG cocktail PET scanning for cancer detection and management is currently underway (25) .
The results of the present study demonstrate that mismatched intratumoral distribution of 18 F-FLT and 18 F-FDG is a common feature of patients with lung cancer and may serve as an indicator of lung malignancy.
